Wall Street brokerages expect Aclaris Therapeutics, Inc. (NASDAQ:ACRS) to report earnings per share of ($0.27) for the current fiscal quarter, Zacks reports. Five analysts have made estimates for Aclaris Therapeutics’ earnings. The highest EPS estimate is ($0.23) and the lowest is ($0.37). Aclaris Therapeutics posted earnings of ($0.28) per share in the same quarter last year, which would suggest a positive year over year growth rate of 3.6%. The business is expected to report its next earnings results on Friday, August 6th.
On average, analysts expect that Aclaris Therapeutics will report full-year earnings of ($1.45) per share for the current year, with EPS estimates ranging from ($1.75) to ($1.22). For the next financial year, analysts forecast that the company will report earnings of ($1.32) per share, with EPS estimates ranging from ($1.45) to ($1.05). Zacks’ EPS averages are a mean average based on a survey of sell-side research analysts that that provide coverage for Aclaris Therapeutics.
Aclaris Therapeutics (NASDAQ:ACRS) last issued its quarterly earnings data on Thursday, May 6th. The biotechnology company reported ($0.57) EPS for the quarter, missing the consensus estimate of ($0.30) by ($0.27). The firm had revenue of $1.78 million for the quarter, compared to the consensus estimate of $1.47 million. Aclaris Therapeutics had a negative net margin of 936.71% and a negative return on equity of 107.60%.
Shares of NASDAQ:ACRS traded down $0.02 during midday trading on Thursday, hitting $15.74. 4,356 shares of the stock traded hands, compared to its average volume of 903,643. The stock’s 50 day simple moving average is $18.95. The company has a current ratio of 9.27, a quick ratio of 9.27 and a debt-to-equity ratio of 0.10. Aclaris Therapeutics has a one year low of $1.82 and a one year high of $30.38.
In other Aclaris Therapeutics news, insider Kamil Ali-Jackson sold 15,000 shares of the company’s stock in a transaction dated Wednesday, May 5th. The shares were sold at an average price of $23.98, for a total value of $359,700.00. Following the sale, the insider now owns 158,618 shares in the company, valued at $3,803,659.64. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider David N. Gordon sold 2,631 shares of the stock in a transaction that occurred on Tuesday, July 13th. The shares were sold at an average price of $16.98, for a total transaction of $44,674.38. Following the transaction, the insider now owns 147,447 shares in the company, valued at approximately $2,503,650.06. The disclosure for this sale can be found here. In the last 90 days, insiders sold 122,138 shares of company stock worth $2,856,286. Corporate insiders own 8.20% of the company’s stock.
Institutional investors and hedge funds have recently bought and sold shares of the stock. Royal Bank of Canada grew its stake in Aclaris Therapeutics by 85.6% during the first quarter. Royal Bank of Canada now owns 3,515 shares of the biotechnology company’s stock valued at $89,000 after acquiring an additional 1,621 shares in the last quarter. Dorsey Wright & Associates lifted its holdings in shares of Aclaris Therapeutics by 135.0% in the 1st quarter. Dorsey Wright & Associates now owns 6,110 shares of the biotechnology company’s stock worth $154,000 after acquiring an additional 3,510 shares during the last quarter. Victory Capital Management Inc. bought a new stake in shares of Aclaris Therapeutics in the 1st quarter worth about $204,000. Squarepoint Ops LLC bought a new stake in shares of Aclaris Therapeutics in the 1st quarter worth about $215,000. Finally, Diametric Capital LP bought a new stake in shares of Aclaris Therapeutics in the 1st quarter worth about $278,000. 87.15% of the stock is owned by institutional investors.
About Aclaris Therapeutics
Aclaris Therapeutics, Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel, small molecule therapeutics to address the needs of patients with immuno-inflammatory diseases. The company has a multi-stage portfolio of drug candidates powered by a research and development engine exploring protein kinase regulation.
See Also: What are the Benefits of Index Funds?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Aclaris Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aclaris Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.